Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| The integration of Palette is progressing well and we expect the acquisition to be a meaningful contributor to our growth in the coming years |
| For the full year 2023, we had a strong performance with revenues reaching $2.975 billion, which represents 6.5% constant currency growth year-over-year, while adjusted earnings per share was $13.52 |
| And again, definitely solid path to the revenue and the solid path to the gross margin line and underlying EPS as we've gone through with a couple of your colleagues underlying EPS is solid |
| And as you know, had positive pricing as a company |
| If you adjust for the days, we delivered a robust 8.1% growth in the fourth quarter |
| While that was happening, China continued to be a real solid double-digit grower for Teleflex |
| So I'm really happy with how the Interventional business is going well |
| We have a really good cadence of new products |
| And I think that I feel as I said, good about the way we've guided and I feel good about our ability to deliver |
| We continue to see really nice growth in the pump business |
| And as Tom walked you through the bridge, our underlying earnings per share growth is really strong -- is really positive |
| And if you look at the total of our favorable pricing, savings from manufacturing, cost improvements, savings from footprint programs, they're able to offset those inflationary pressures as well as some capitalized balances that are on the balance sheet and will rollout in the P&L in 2024 |
| Urology products, Interventional and Vascular businesses generated the highest shipping days adjusted growth in the quarter |
| Kristen Stewart The Interventional business grew very nicely in this quarter and 15% for the full year on a constant currency basis |
| Liam Kelly We had a good year with price in 2023, we exceeded our goal of 50 basis points and came in above that |
| The performance in the quarter was driven by strong commercial execution and solid underlying demand |
| And therefore, we do believe that our business is well capable of driving that high single digits into the double digits |
| The fourth quarter was strong |
| Of note, we achieved double-digit growth in our underlying PICC business when excluding the negative impact of the Endurance recall |
| We continue to see opportunities for share gains in the peripheral access markets and our new product initiatives will help play a role |
| And as we head into the second year of the LRP, I feel confident in our ability to deliver the current guidance and that will be the springboard into next year, the final year of the LRP |
| Despite the impact of the fewer selling days, we demonstrated solid growth, which underscores our positive momentum as we continue to make good progress with our growth drivers |
| Among our larger product categories, hemostatic products performed well in the quarter, with strong double-digit growth, partially offset by declines in atomization and ET Tubes, as we recover from the recall, which occurred earlier in 2023 |
| Our underlying trends in our core surgical franchise continue to be solid, including our ligation portfolio |
| So Japan is doing exceptionally well |
| Revenues in the fourth quarter were modestly better than expectations with outperformance of Barrigel |
| I feel really good about the LRP |
| OEM had another solid quarter, with revenues increasing 10.9% year-over-year to $82.6 million |
| The strength in the quarter was broad-based across our portfolio, with all product categories recording year-over-year growth, including continued strength in microcatheters |
| And as a team, I think we feel really confident in our ability to deliver on all aspects of it |
| Statement |
|---|
| In our Surgical business, revenue was $109.6 million, down 2% year-over-year against a tough comparison |
| Fourth quarter Other revenue declined 10.2% to $68.2 million year-over-year |
| At the bottom line, fourth quarter adjusted earnings per share was $3.38, a decrease of 4% versus prior year |
| Fourth quarter adjusted earnings per share was $3.38 a 4% decrease year-over-year |
| Revenue declined 3.4% year-over-year to $98.2 million |
| And the reason that the quarter 1 is a little bit dampened is, as I said, there's a few tough comps in the mix there |
| EMEA revenues of $152.4 million decreased 2.7% year-over-year, driven by Anesthesia and Surgical and reflective of the impact of the fewer shipping days |
| I appreciate your comments about the operating margin, LRP being a bit challenging for '25 |
| Americas revenues were $450.6 million, a 1.9% decrease year-over-year, driven by Surgical and Vascular and reflective of the 5 fewer shipping days in the quarter |
| With regard to the sites of service, we again grew in the hospital site of service in Q4, but it's again, the office, unfortunately, is still challenging for us just because of the reimbursement change that was made there |
| For UroLift, the office remains a challenge as we continue our efforts to stabilize this size of service |
| Netting the loss of MSA revenues, the incremental Palette sales and foreign exchange headwinds represents an approximately 100 basis point year-over-year headwind to growth in 2024 |
| And I think even though the up margin targets will be a challenge |
| In addition to the inflation headwinds, we're also experiencing a modest adverse impact from foreign exchange |
| Liam Kelly I'm sorry, the line is incredibly bad and we're having great difficulty hearing you |
| Relative to foreign exchange, although there is a negligible impact on revenue, the headwind to earnings per share is approximately $0.24 year-over-year |
| And it will be tougher for us to get to the up margin goal in all transparency and I think the investment community know that |
| Revenue decreased 1.2% to $186.7 million |
| The office business you highlighted that's still seeing some challenges in the U.S |
| MANTA will have a tough comp next year |
Please consider a small donation if you think this website provides you with relevant information